SLAMF7 and Miyoshi myopathy: The PVX-410 vaccine, mimicking three MM-associated antigens, X-box binding protein 1 (XBP1), syndecan-1 (CD138), and SLAM family member 7 (SLAMF7), has shown safety and immunogenicity in SMM patients, and more novel vaccines are under investigation in SMM and MGUS patients [22–25].